Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Merck Sharp & Dohme LLC
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patient must be 18 years or older with relapsed Diffuse Large B-cell Lymphoma (DLBCL).
Stable disease or better for at least 3 months on most recent treatment
Have not received any chemotherapy, radiation therapy, major surgery, or any other investigational therapy for at least 4 weeks prior to entry in this study
Adequate blood testing, liver, and kidney function as required by the study.
Eligible subjects will allow tissue samples to be examined and stored.
You may not be if
Patient has been treated with other investigational agents with a similar anti-tumor mechanism.
Patient should not have failed more than 3 prior treatment regimens.
Clareo Health | An Investigational Drug Study With Suberoylanilide Hydroxamic Acid in Relapsed Diffuse Large B-cell Lymphoma (0683-013)
